Century Therapeutics, Inc.
Century Therapeutics, Inc. (IPSC) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · IPSC · as of Sep 30, 2025
Ownership Breakdown
54
Institutional Holders
▼ 13 vs Q2
$10.12M
Total Inst. Value
▼ $2.53M vs Q2
86.57M
Shares Outstanding
freeFloat 56.19%
20.30M
13F Shares Held
▼ 2.32M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
IPSC largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 3.54M | 4.10% | 4.10% | $1.76B | Nov 14, 2025 | ▼ 1.87M |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 2.59M | 3.00% | 3.00% | $1.29B | Nov 13, 2025 | ▲ 564.4K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.10M | 2.44% | 2.44% | $1.05B | Nov 7, 2025 | ▼ 6.2K |
DAFNA CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.70M | 1.98% | 1.98% | $848.71M | Nov 14, 2025 | — held |
CASDIN CAPITAL, LLC biological products, (no diagnostic substances) | 1.23M | 1.42% | 1.42% | $611.64M | Nov 14, 2025 | — held |
SYNCONA PORTFOLIO LTD biological products, (no diagnostic substances) | 1.21M | 1.41% | 1.41% | $604.10M | Nov 6, 2025 | — held |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 911.4K | 1.06% | 1.06% | $453.90M | Nov 14, 2025 | ▲ 338.9K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 900.0K | 1.04% | 1.04% | $448.20M | Nov 14, 2025 | — held |
TWO SIGMA ADVISERS, LP biological products, (no diagnostic substances) | 857.6K | 99.45% | 99.45% | $427.08M | Nov 14, 2025 | ▲ 490.5K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 743.8K | 86.25% | 86.25% | $370.40M | Nov 14, 2025 | ▼ 68.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+2.42M shares2
New Positions
first time holders25
Decreased
−4.32M shares0
Sold Out
fully exitedNet shares change (top 50)
1.90M
+2.42M / −4.32M
Net new holders
-13
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
IPSC insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Pfeiffenberger Brent President and CEO | May 15, 2026 | Tax Withhold | 31,172 | $2.34 | $72.9K | 3.68M | Form 4 ↗ |
Carr Douglas SVP Finance & Operations | May 4, 2026 | Sale | 264 | $2.34 | $618.024 | 507.0K | Form 4 ↗ |
Murphy Martin Patrick director | Dec 9, 2025 | Award | 88,000 | $0.59 | $52.1K | 88.0K | Form 4 ↗ |
Cowan Chad Chief Scientific Officer | Apr 1, 2026 | Tax Withhold | 1,365 | $2.19 | $3.0K | 1.18M | Form 4 ↗ |
Carr Douglas SVP Finance & Operations | Mar 12, 2026 | Sale | 7,043 | $2.55 | $18.0K | 507.3K | Form 4 ↗ |
Russotti Gregory See Remarks | Mar 12, 2026 | Sale | 10,076 | $2.55 | $25.7K | 515.4K | Form 4 ↗ |
Pfeiffenberger Brent President and CEO | Mar 11, 2026 | Tax Withhold | 55,397 | $2.73 | $151.2K | 3.71M | Form 4 ↗ |
Cowan Chad Chief Scientific Officer | Mar 11, 2026 | Tax Withhold | 1,431 | $2.73 | $3.9K | 1.18M | Form 4 ↗ |
Russotti Gregory See Remarks | Mar 9, 2026 | Sale | 479 | $2.54 | $1.2K | 525.5K | Form 4 ↗ |
Pfeiffenberger Brent President and CEO | Mar 6, 2026 | Tax Withhold | 463 | $2.56 | $1.2K | 3.77M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Century Therapeutics, Inc. (IPSC) is primarily owned by institutional investors, who hold approximately 23.4% of total shares outstanding. Company insiders own approximately 43.81%, while retail and public investors account for the remaining 32.74%.
The largest institutional shareholder of Century Therapeutics, Inc. is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding approximately 3.54 million shares — equal to 4.10% of outstanding shares — as of September 30, 2025.
A total of 54 institutional investors currently hold IPSC stock, with a combined institutional value of approximately $10,115,451 as of the most recent 13F filing period.
Frequently asked questions
IPSC ownershipCentury Therapeutics, Inc. (IPSC) is primarily owned by institutional investors, who hold approximately 23.4% of shares. The largest shareholder is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with a 4.10% stake. Company insiders hold 43.81%. Data sourced from SEC Form 13F as of September 30, 2025.